Related Experiment Video
Updated: Jun 3, 2025
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Statin therapy in ischemic stroke patients with atrial fibrillation: Efficacy and safety outcomes
Michele Marvardi1, Maurizio Paciaroni1,2, Valeria Caso1
1Stroke Unit and Division of Cardiovascular Medicine, University of Perugia, Perugia, Italy.
Insights
Statins may reduce bleeding risk in patients with cardioembolic stroke and atrial fibrillation (AF). This study found statin use was associated with a lower risk of hemorrhagic events, though not overall ischemic events. Further research is needed.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Secondary prevention efficacy and safety of statins in cardioembolic stroke patients with atrial fibrillation (AF) remain unclear.
- Hyperlipidemia is a known risk factor for both ischemic and bleeding complications in AF patients with prior stroke.
- Previous observational data suggest potential benefits of statins in stroke patients.
Purpose of the Study:
- To evaluate the efficacy and safety of statins for secondary prevention in patients experiencing acute ischemic stroke with AF.
- To assess the impact of statin use on both ischemic and hemorrhagic outcomes in this patient population.
Main Methods:
- A sub-analysis of the prospective observational RAF and RAF-NOAC studies was conducted.
- Data from 1742 patients with AF and acute ischemic stroke were analyzed (January 2012-June 2016).
- Outcomes included a composite endpoint of stroke, TIA, systemic embolism, ICH, and major extracranial bleeding, analyzed separately for ischemic and hemorrhagic events over 90-day follow-up.
Main Results:
- Statin use was not associated with a reduced risk of the combined or ischemic outcome events.
- Statin use was significantly associated with a lower risk of hemorrhagic outcome events (OR 0.51, 95% CI 0.28-0.91, p=0.02).
- Multivariable analysis identified factors associated with statin use, including age, male sex, anticoagulation, hyperlipidemia, paroxysmal AF, leukoaraiosis, and heart failure.
Conclusions:
- Statins may offer protection against global bleeding events in patients with cardioembolic stroke, potentially due to their pleiotropic effects.
- The findings suggest a potential benefit of statins in reducing hemorrhagic complications in this patient group.
- Further research is warranted to confirm these findings and elucidate the mechanisms behind the observed effects.
Introduction:
The efficacy and safety of statins for secondary prevention in patients who have experienced a cardioembolic stroke are not well-defined. However, previous observational data reported hyperlipidemia as a risk factor for both ischemic and bleeding complications in patients with AF and previous stroke. Based on these premises, we conducted a sub-analysis of the RAF and RAF-NOAC studies to evaluate the efficacy and safety of statins in secondary prevention in patients with acute ischemic stroke and AF.
Materials And Methods:
We combined patient data from the RAF and RAF-NOAC studies, prospective observational studies conducted across Stroke Units in Europe, the United States, and Asia from January 2012 to June 2016. We included consecutive patients with AF who suffered an acute ischemic stroke with a follow-up of 90 days. Our outcomes were the combined endpoint, including stroke, transient ischemic attack, systemic embolism, symptomatic intracerebral hemorrhage, and major extracranial bleeding. Furthermore, both ischemic and hemorrhagic outcomes were evaluated separately.
Results:
A total of 1742 patients were included (46% male), and 898 (52%) received statins after the index event, of whom 436 (48.6%) were already taking statins before the index event, 462 (51.4%) started treatment after. At multivariable analysis, statin use was statistically associated with age (OR 0.92, 95% CI 0.97-0.99, p = 0.001), male sex (OR 1.35, 95% CI 1.07-1.70, p = 0.013), anticoagulation (OR 2.53, 95% CI 1.90-3.36, p < 0.0001), hyperlipidemia (OR 5.52, 95% CI 4.28-7.12, p < 0.0001), paroxysmal AF (OR 1.40, 95% CI 1.12-1.75, p = 0.003), leukoaraiosis (OR 1.39, 95% CI 1.11-1.75, p = 0.004) and heart failure (OR 0.72, 95% CI 0.53-0.98, p = 0.034). Statin use was not associated with the combined outcome event (OR 0.84, 95% CI 0.58-1.23, p = 0.3) and ischemic outcome event (OR 1.17, 95% CI 0.73-1.88, p = 0.5) while was associated with a lower risk of hemorrhagic outcome event (OR 0.51, 95% CI 0.28-0.91, p = 0.02).
Discussion:
Statins protect cerebral arterial vessels (particularly small vessels) from subacute damage due to hypertension, diabetes, and other harmful agents (such as reactive oxygen species, proinflammatory cytokines, etc.) due to their systemic anti-inflammatory and endothelium-protective effects.
Conclusions:
Our data show that statins seem to protect against global bleeding events in cardioembolic stroke patients; this may be due to the pleiotropic effect of statins. More data are warranted to confirm these findings.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers